fig2

Longitudinal monitoring for the emergence of epidermal growth factor C797S resistance mutations in non-small cell lung cancer using blood-based droplet digital PCR

Figure 2. Evolution of EGFR del19, T790M, and C797S during the 540-day osimertinib treatment cycle. Data are displayed as relative fluorescence units, and the calculated %MVF values are shown for each test. A and B: Del19 on days 0 and 540, respectively; C and D: T790M on days 0 and 540, respectively; E and F: C797S on days 0 and 540, respectively. EGFR L858R was consistently found to be negative by both ddPCR and NGS tests (data not shown). EGFR: epidermal growth factor; %MVF: percent minor variant frequency; ddPCR: droplet digital PCR; NGS: next-generation sequencing

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/